TRVI: חוב כולל להון Trevi Therapeutics, Inc.

Trevi Therapeutics (TRVI) currently lacks pricing power and relies on external capital. The total liabilities-to-equity ratio visualizes this dependency, where the value of 0.00 shows the current level of debt load. This situation is driven by management's focus on neurological drugs and strict compliance with environmental standards for chemical waste disposal in laboratories.

The financial stability of Trevi Therapeutics (TRVI) is based on the control of its debt load. The total debt-to-equity ratio measures the proportion of borrowed funds within the asset structure, determining the risk of insolvency. An increase in this metric signals excessive leverage. Low reliance on loans allows the company to confidently develop unique cough medications. An optimal capital balance confirms the fair market value of the business.